1 / 6

CAST: Cardiac Arrhythmia Suppression Trial

CAST: Cardiac Arrhythmia Suppression Trial. Purpose To determine whether therapy with class Ic antiarrhythmics to suppress asymptomatic or mildly symptomatic ventricular arrhythmias after MI reduces mortality due to arrhythmia Reference

vonda
Télécharger la présentation

CAST: Cardiac Arrhythmia Suppression Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CAST: Cardiac Arrhythmia Suppression Trial Purpose To determine whether therapy with class Ic antiarrhythmics to suppress asymptomatic or mildly symptomatic ventricular arrhythmias after MI reduces mortality due to arrhythmia Reference The CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406–12.

  2. CAST: Cardiac Arrhythmia Suppression Trial- TRIAL DESIGN - Design Multicenter, multinational; initial phase open; main phase randomized, double-blind, placebo-controlled Patients 1725 patients with >6 ventricular premature depolarizations/h (24h Holter recording) and left ventricular ejection fraction <0.55 at <90 days after MI or <0.40 at >90 days after MI Follow up and primary end point Mean 10 months follow up. Primary endpoint death from arrhythmia Treatment • Open titration phase (mean 15 days) to select patients in whom drug (encainide, flecainide or moricizine) suppressed arrhythmias • Selected patients then randomized to three-times daily placebo, encainide 35–50 mg, flecainide 100 mg or moricizine 200–250 mg (results for moricizine not reported here)

  3. CAST: Cardiac Arrhythmia Suppression Trial- RESULTS - • Study of encainide/flecainide vs. placebo halted at mean follow up of 10 months on recommendation of CAST Data and Safety Monitoring Board because in group taking encainide or flecainide, compared with placebo group: • All-cause mortality significantly higher • Non-fatal cardiac arrest or death from arrhythmia significantly higher • Death from other cardiac causes also higher • Results consistent across all subgroups examined • No confounding factors were identified to explain marked differences between encainide/flecainide and placebo • Study subsequently modified to continue with moricizine (CAST II)

  4. CAST: Cardiac Arrhythmia Suppression Trial- RESULTS continued- All-cause mortality Survival 100 (%) 95 90 85 Placebo (n=725) Encainide or flecainide (n=730) P=0.0003 80 0 50 100 150 200 250 300 350 400 450 500 Days after randomization CAST Investigators. N Engl J Med 1989; 321 :406 – 12.

  5. CAST: Cardiac Arrhythmia Suppression Trial- RESULTS continued- Mortality and cardiac arrest Placebo Encainide/flecainide Relative risk (n=725) (n=730) (95% CI) No. (%) No. (%) Non-fatal cardiac arrest 9 (1.2) 33 (4.5) 3.6 (1.7 – 8.5) or death from arrhythmia Other cardiac death 6 (0.8) 14 (1.9) – Non-cardiac or unclassified death 7 (1.0) 9 (1.2) – or cardiac arrest Total death or cardiac arrest 22 (3.0) 56 (7.7) 2.5 (1.6 – 4.5) 300 293 Average days of exposure CAST Investigators. N Engl J Med 1989; 321 :406 – 12.

  6. CAST: Cardiac Arrhythmia Suppression Trial- SUMMARY - In patients with asymptomatic or mildly symptomatic ventricular arrhythmias after MI, encainide or flecainide started at mean of 15 days after MI caused: • Excessive mortality risk • Excessive risk of death from arrhythmia

More Related